Consilium MedicumConsilium MedicumConsilium MedicumConsilium Medicum2075-17532542-2170Consilium Medicum93791ArticlesСтатьиResearch ArticleTsefiksim. Klinicheskaya effektivnost' pri obostrenii netyazheloy khronicheskoy obstruktivnoy bolezni legkikh i vliyanie na razvitie retsidivov zabolevaniya. Nablyudatel'naya programmaЦефиксим. Клиническая эффективность при обострении нетяжелой хронической обструктивной болезни легких и влияние на развитие рецидивов заболевания. Наблюдательная программаGuchevI. AГучевИ. АSafonovaE. VСафоноваЕ. ВTsoyA. NЦойА. НФилиал №4 ФГУ 1586 Окружной военный клинический госпиталь Московского военного округа Минобороны РФ, СмоленскГКБ №23 им. Медсантруд ДЗ г. Москвы2ГКБ №23 им. Медсантруд ДЗ г. Москвы15032013153VOL 15, NO3 (2013)ТОМ 15, №3 (2013)727828122021Copyright ©; 2013, Consilium MedicumCopyright ©; 2013, ООО "Консилиум Медикум"2013Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://consilium.orscience.ru/2075-1753/article/view/93791

Хронический обструктивный бронхит характеризуется хроническим, диффузным, неаллергическим воспалением бронхов, ведущим к прогрессирующему нарушению легочной вентиляции и газообмена по обструктивному типу. Он проявляется кашлем, одышкой и ежедневным отделением мокроты в течение по крайней мере 3 мес на протяжении двух последовательных лет, не связанными с поражением других органов и систем.

хронический бронхитхроническая обструктивная болезнь легкихцефиксимAmerican Thoracic Society. Chronic bronchitis, asthma, and pulmonary emphysema: a statement by the Committee on Diagnostic Standards for Nontuberculous Respiratory Diseases. Am review respir diseases 1962; 85: 762–8.Fletcher C, Peto R. Natural history of chronic constriction of respiratory tract (author\'s transl). Przeglad lekarski 1978; 35: 747–52.Seemungal T.A., Hurst J.R., Wedzicha J.A. Exacerbation rate, health status and mortality in COPD – a review of potential interventions. Int J Chron Obstruct Pulmon Dis 2009; 4: 203–23.Vestbo J, Hurd S.S., Agusti A.G. et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: GOLD Executive Summary. Am J Respir Critical Care Med 2013; 187: 347–65.Lindenauer P.K., Pekow P, Gao S et al. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2006; 144: 894–903.Anthonisen N.R., Manfreda J, Warren C.P. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196–204.Ram F.S., Rodriguez-Roisin R, Granados-Navarrete A et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane database of systematic reviews (Online) 2006: CD004403.The OMBIRT Consensus Panel. Outpatient Management of Bacterial Infections in the Lower Respiratory Tract (OMBIRT): Diagnosis, Evaluation, and Antibiotic Selection in the Primary Care Setting. Atlanta, Ga: American Health Consultants, 2001.Wilkinson T.M., Donaldson G.C., Hurst J.R. et al. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Critical Care Med 2004; 169: 1298–303.Seemungal T.A.R., Harper-Owen R, Bhowmik A et al. Respiratory viruses, symptoms and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Critical Care Med 2001; 164: 1618–23.Rohde G, Wiethege A, Borg I et al. Respiratory viruses in exacerbations of chronic obstructive pulmonary disease requiring hospitalisation: a case - control study. Thorax 2003; 58: 37–42.Qiu Y, Zhu J, Bandi V et al. Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease. Am J Respir Critical Care Med 2003; 168: 968–75.Stockley R.A., O\'Brien C, Pye A, Hill S.L. Relationship of sputum color to nature and outpatient management of acute exacerbations of COPD. Chest 2000; 117: 1638–45.Alvarez-Sala J.L., Kardos P, Martinez-Beltran J et al. Clinical and bacteriological efficacy in treatment of acute exacerbations of chronic bronchitis with cefditoren - pivoxil versus cefuroxime - axetil. Antimicrob Agents Chemother 2006; 50: 1762–7.Fogarty C.M., Bettis R.B., Griffin T.J. et al. Comparison of a 5 day regimen of cefdinir with a 10 day regimen of cefprozil for treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemotner 2000; 45: 851–8.Miravitlles M, Espinosa C, Fernandez-Laso E et al. Relationship between bacterial flora in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection in COPD. Chest 1999; 116: 40–6.Ko W.C., Paterson D.L., Sagnimeni A.J. et al. Community - acquired Klebsiella pneumoniae bacteremia: global differences in clinical patterns. Emerg Infect Dis 2002; 8: 160–6.Козлов Р.С., Сивая О.В., Шпынев К.В. и др. Антибиотикорезистентность Streptococcus pneumoniae в России в 1999–2005 гг.: результаты многоцентровых проспективных исследований ПеГАС–I и ПеГАС–II. Клин. микробиология и антимикроб. химиотерапия. 2006; 8: 33–47.Lorenz J, Steinfeld P, Drath L et al. Efficacy and tolerability of 5 vs 10 day cefixime therapy in acute exacerbations of chronic bronchitis. Clin Drug Invest 1998; 15: 13–20.Neu H.C., Chick T.W. Efficacy and safety of clarithromycin compared to cefixime as outpatient treatment of lower respiratory tract infections. Chest 1993; 104: 1393–9.Quintiliani R. Cefixime in the treatment of patients with lower respiratory tract infections: results of US clinical trials. Clin Ther 1996; 18: 373–90; discussion 2.National Heart, Lung and Blood Institute, World Health Organization. Workshop report: global strategy for the diagnosis, management, and prevention of COPD: updated 2007. Available from URL: http://www.goldcopd.org.Mandell L.A., Wunderink R.G., Anzueto A et al. Infectious diseases society of america/american thoracic society consensus guidelines on the management of community – acquired pneumonia in adults. Clin Infect Dis 2007; 44 (Suppl. 2): S27–72.Chow A.W., Hall C.B., Klein J.O. et al. Evaluation of new anti–infective drugs for the treatment of respiratory tract infections. Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992; 15 (Suppl. 1): S62–88.Chodosh S. Clinical significance of the infection – free interval in the management of acute bacterial exacerbations of chronic bronchitis. Chest 2005; 127: 2231–6.Dimopoulos G, Siempos, II, Korbila I.P. et al. Comparison of first - line with second - line antibiotics for acute exacerbations of chronic bronchitis: a metaanalysis of randomized controlled trials. Chest 2007; 132: 447–55.Destache C.J., Dewan N, O\'Donohue W.J. et al. Clinical and economic considerations in the treatment of acute exacerbations of chronic bronchitis. J Аntimicrob Chemother 1999; 43 (Suppl. A): 107–13.Georgopoulos A, Borek M, Ridl W. Randomized, double–blind, double–dummy study comparing the efficacy and safety of amoxicillin 1 g bd with amoxycillin mg tds in the treatment of acute exacerbations of chronic bronchitis. J Antimicrob Chemother 2001; 47: 67–76.Canut A, Martin-Herrero J.E., Labora A, Maortua H. What are the most appropriate antibiotics for the treatment of acute exacerbation of chronic obstructive pulmonary disease? A therapeutic outcomes model. J Antimicrob Chemother 2007; 60: 605–12.White A.J., Gompertz S, Bayley D.L. et al. Resolution of bronchial inflammation is related to bacterial eradication following treatment of exacerbations of chronic bronchitis. Thorax 2003; 58: 680–5.Chodosh S, McCarty J, Farkas S et al. Randomized, double - blind study of ciprofloxacin and cefuroxime axetil for treatment of acute bacterial exacerbations of chronic bronchitis. The Bronchitis Study Group. Clin Infect Dis 1998; 27: 722–9.Zuck P, Petitpretz P, Geslin P et al. Bacteriological eradication of Streptococcus pneumoniae from patients with acute exacerbations of chronic bronchitis: cefuroxime axetil versus cefixime. Intern J Clin Practice 1999; 53: 437–43.Arthur M, McAdoo M, Guerra J et al. Clinical comparison of cefuroxime axetil with cefixime in the treatment of acute bronchitis. Am J Ther 1996; 3: 622–9.Lieberman D, Schlaeffer F. Once - a - day cefixime versus co - amoxiclav three times daily in the treatment of lower respiratory infections. J Antimicrob Chemother 1995; 35: 354–7.Vogel F, Scholz H, al. Nawas B et al. Rational use of oral antibiotics. Findings of an expert commission of the Paul Ehrlich Society for Chemotherapy. Medizinische Monatsschrift fur Pharmazeuten 2002; 25: 193–204.Blumer J.L. Pharmacokinetics and pharmacodynamics of new and old antimicrobial agents for acute otitis media. Pediatr Infect Disease J 1998; 17: 1070–5; discussion 99–100.Klepser M.E., Marangos M.N., Patel K.B. et al. Clinical pharmacokinetics of newer cephalosporins. Clin Pharm 1995; 28: 361–84.Silber D.M., Bohaychuk W, Stout M et al. Pharmacokinetics of cefixime in young and elderly volunteers. Workshop. 15th International Congress of Chemotherapy, Jul 87. Adv Exp Clin Chemother 1988; 1: 18–20.Stone J.W., Linong G, Andrews J.M., Wise R. Cefixime, in - vitro activity, pharmacokinetics and tissue penetration. J Antimicrob Chemother 1989; 23: 221–8.Baldwin D.R., Andrews J.M., Ashby J.P. et al. Concentrations of cefixime in bronchial mucosa and sputum after three oral multiple dose regimens. Thorax 1990; 45: 401–2.Maesen F.P., Costongs R, Davies B.I. Concentrations of cefixime in bronchial mucosa and sputum. Thorax 1990; 45: 982–3.Wise R. The pharmacokinetics of the oral cephalosporins – a review. J Antimicrob Chemother 1990; 26 (Suppl. E): 13–20.Grellet J, Couraud L, Saux M.C., Roche G. Pulmonary diffusion of cefixime in man. Presse Med 1989; 18: 1589–92.Craig W.A., Ebert S.C. Killing and regrowth of bacteria in vitro: a review. Scand J Infect Dis (Suppl.) 1990; 74: 63–70.CLSI. Performance Standards for Antimicrobial Susceptibility Testing; Seventeenth Informational Supplement. CLSI document M100–S17. Waynre, PA: Clinical and Laboratory Standards Institute, 2007.Fenoll A, Robledo O, Lerma M et al. Activity of cefpodoxime and other oral beta - lactams against Haemophilus influenzae and Streptococcus pneumoniae with different susceptibilities to penicillin. Rev Esp Quimioter 2006; 19: 39–44.Kardas P. Non - compliance - some myths, some facts. Casopis Lekaru Ceskych 2004; 143: 556–9; discussion 60.Kardas P. Patient non - compliance as a cause of treatment failure. Pol Merkur Lekarski 2000; 9: 732–5.Garau J, Twynholm M, Garcia-Mendez E et al. Oral pharmacokinetically enhanced co - amoxiclav 2000/125 mg, twice daily, compared with co - amoxiclav 875/125 mg, three times daily, in the treatment of community - acquired pneumonia in European adults. J Antimicrob Chemother 2003; 52: 826–36.Henry D.C., Riffer E, Sokol W.N. et al. Randomized double - blind study comparing 3- and 6-day regimens of azithromycin with a 10-day amoxicillin - clavulanate regimen for treatment of acute bacterial sinusitis. Antimicrob Agents Chemother 2003; 47: 2770–4.Leophonte P, File T, Feldman C. Gemifloxacin once daily for 7 days compared to amoxicillin/clavulanic acid thrice daily for 10 days for the treatment of community - acquired pneumonia of suspected pneumococcal origin. Respir Med 2004; 98: 708–20.Arrieta J.R., Galgano A.S., Sakano E et al. Moxifloxacin vs amoxicillin/clavulanate in the treatment of acute sinusitis. Am J Otolaryngol 2007; 28: 78–82.Poirier R, Chardon H, Beraud A et al. Efficacy and tolerability of pristinamycin vs amoxicillin - clavulanic acid combination in the treatment of acute community - acquired pneumonia in hospitalized adults. Rev Pneumol Clin 1997; 53: 325–31.File T.M., Lode H, Kurz H et al. Double - blind, randomized study of the efficacy and safety of oral pharmacokinetically enhanced amoxicillin - clavulanate (2,000/125 milligrams) versus those of amoxicillin - clavulanate (875/125 milligrams), both given twice daily for 7 days, in treatment of bacterial community - acquired pneumonia in adults. Antimicrob Agents Chemother 2004; 48: 3323–31.Neu H.C., Wilson A.P., Gruneberg R.N. Amoxycillin/clavulanic acid: a review of its efficacy in over 38,500 patients from 1979 to 1992. J Chemother (Florence, Italy) 1993; 5: 67–93.Siquier B, Sanchez-Alvarez J, Garci-Mendez E et al. Efficacy and safety of twice - daily pharmacokinetically enhanced amoxicillin/clavulanate (2000/125 mg) in the treatment of adults with community - acquired pneumonia in a country with a high prevalence of penicillin - resistant Streptococcus pneumoniae. J Antimicrob Chemother 2006; 57: 536–45.Ren X, Liu D, Ding N et al. Safety evaluation of cephalosporins based on utilization and adverse drug events: analysis of two databases in China. Exp Opinion Drug Safety 2012; 11: 689–97.